Not Accepting Cases

Morcellator Complications

Morcellators are used in minimally invasive surgery to remove fibroids from the uterus or to completely remove the uterus in a hysterectomy. They use rapidly spinning blades to tear tissue into tiny pieces that can be removed through a small incision. But if they hit an undetected cancer tumor, they can spread the cancer and make it more difficult to treat.

Power morcellators do not cause cancer, but they can spread it inside the abdominal cavity. This is the part of the body that contains the intestines, liver, kidneys, reproductive and other organs.

The U.S. Food and Drug Administration estimates that approximately 1 in 225 to 1 in 580 women who undergo surgery for uterine fibroids have undetected uterine cancer. Studies have found that a hidden uterine sarcoma may be present in roughly 1 in 350 women who undergo a hysterectomy or myomectomy.

When the spinning blades of a power morcellator hit these cancer tumors, it can tear them into tiny pieces and spread the cells like seeds through the area around the surgical site. These cells effectively take root and can grow into new tumors. This significantly reduces the patient’s chances of long-term survival.

Uterine Cancer Risks

When power morcellators spread uterine cancer, it often isn’t detected until it has advanced to later stages and is difficult to treat.

The American Association of Gynecologic Laparoscopists reviewed one study of 1,091 power morcellator surgeries and found that 12 women had irregular tissue samples not previously diagnosed. Ten of these women had malignant cancer cells. Types of cancer found included uterine myoma, endometrial stromal sarcoma (ESS) and leiomyosarcoma (LMS).

Spreading Leiomyosarcoma (LMS)

Leiomyosarcoma is one of the more serious types of uterine cancer these instruments can spread. It is particularly deadly and aggressive.

According to the FDA, a leiomyosarcoma may be present in an estimated 1 in 495 to 1 in 1100 women who undergo surgery for uterine fibroids.

This type of soft tissue sarcoma is most common in the uterus, abdomen or pelvis. Left untreated, it can spread through the bloodstream, affecting the lungs, liver, blood vessels or any other soft tissue in the body.

MRIs, CT scans and even biopsies are not 100 percent reliable in detecting these hidden cancer cells. But, endometrial cancers are easier to find than more aggressive forms like LMS. Before undergoing surgery, women should have a biopsy of the uterine lining.

In a pivotal study by Dr. Jason D. Wright and colleagues published in the September 2014 issue of JAMA, the authors stressed the importance of screening hysterectomy or myomectomy patients for any history of cancer before laparoscopic power morcellation. Women with any history of cancer should not undergo this type of procedure.

Anita Austin had laparoscopic power morcellation surgery to remove a uterine fibroid. Doctors told Austin that the procedure would be less invasive and she would recover faster, but they did not inform her of the cancer risk, even though she had previously had thyroid cancer. The cells in her uterus were only Stage I, but the procedure seeded the cells all over her abdomen, effectively advancing the cancer to a higher stage.

“The big issue for me is that no one mentioned cancer,” Austin told Fred Hutch News, “Not at all. And I question things. I’d had thyroid cancer [in the early ‘80s], and I would have probably done something different. Given my history, honestly, I should have been advised not to do it.”

“The big issue for me is that no one mentioned cancer.”

Source: Anita Austin, patient of laparoscopic power morcellation surgery

Frequently, LMS is diagnosed post-surgery after pathologists examine tissue samples. Unfortunately, if one of these instruments was used to extract that tissue, the hidden cancer may have spread, becoming metastatic LMS.

Treatment for LMS typically involves a combination of surgery, chemotherapy and radiation therapy.

Survival and Spread of Cancer

Typically, cancer is easiest to treat if it is “localized” — meaning it has not spread from the uterine. Treatment becomes more difficult if cancer becomes “regionalized” — meaning it has spread to other organs or tissue in the abdomen; or if it has become “distant” — meaning the cancer has spread to the rest of the body.

How Many Women Survive 5 Years or More After Uterine Sarcoma Diagnosis?

Diagram showing number of women that survive after LMS diagnosis
Leiomyosarcoma (LMS)
  • Localized - 6 in 10
  • Regionalized - 4 in 10
  • Distant - 1 in 10
Diagram showing number of women that survive after undifferentiated sarcoma diagnosis
Undifferentiated Sarcoma
  • Localized - 7 in 10
  • Regionalized - 4 in 10
  • Distant - 2 in 10
Diagram showing number of women that survive after endometrial stromal sarcoma
Endometrial Stromal Sarcoma
  • Localized - Almost 10 in 10
  • Regionalized - 9 in 10
  • Distant - 7 in 10

Uterine Cancer Symptoms After Morcellation

When doctors diagnose cancer after morcellation, it is typically stage III or IV — a very advanced stage with poor prognosis. A tumor is considered stage IV when it has spread to the lymph nodes, bladder, rectum and/or distant organs. Some patients had LMS spread to their spine or lungs.

Symptoms that could signal upstaged cancer after morcellation include:
  • Vaginal bleeding or spotting, between periods or especially after menopause
  • Vaginal discharge
  • Pelvic or abdominal pain or a mass
  • Pelvic or abdominal swelling
  • Weight loss
  • Nausea or vomiting

If tumors affect other organs or bones such as the spine, symptoms could include back pain or nerve issues.

Other Complications

In addition to the risk of spreading cancer, surgery with one of these instruments has other risks as well. The devices can even scatter noncancerous fibroid tissue. This can attach to other tissues and organs in the abdominal cavity, causing more fibroids to grow.

Possible complications include:
  • Additional surgery
  • Bleeding or infection
  • Bowel obstruction
  • Bruising
  • Fibroid recurrence
  • Intestinal obstruction from new fibroids
  • Intra-abdominal abscesses
  • Muscle soreness
  • Oozing at incision site
  • Organ damage
  • Pain at incision site
  • Pelvic and abdominal pain
  • Peritonitis (inflammation of the abdominal lining)

Please seek the advice of a medical professional before making health care decisions.

Terry Turner
Written By Terry Turner Writer

Terry Turner has been writing articles and producing news broadcasts for more than 25 years. He covers FDA policy, proton pump inhibitors, and medical devices such as hernia mesh, IVC filters, and hip and knee implants. An Emmy-winning journalist, he has reported on health and medical policy issues before Congress, the FDA and other federal agencies. Some of his qualifications include:

  • American Medical Writers Association (AMWA) and The Alliance of Professional Health Advocates member
  • Centers for Disease Control and Prevention Health Literacy certificates
  • Original works published or cited in Washington Examiner, MedPage Today and The New York Times
  • Appeared as an expert panelist on hernia mesh lawsuits on the BBC
Edited By
Medically Reviewed By
Dr. John A. Daller
Dr. John A. Daller American Board of Surgery

14 Cited Research Articles

  1. ACOG Fellows. (2014, May). Power Morcellation and Occult Malignancy in Gynecologic Surgery. The American College of Obstetricians and Gynecologists. Retrieved from http://www.acog.org/Resources_And_Publications/
  2. American Cancer Society. (2014, May 12). Survival Rates for Uterine Sarcoma by Stage. Retrieved from: https://www.cancer.org/cancer/uterine-sarcoma/detection-diagnosis-staging/survival-rates.html
  3. Brody, J. (2014, March 17). A Surgical Procedure’s Risks, Unmentioned. Retrieved from: http://well.blogs.nytimes.com/2014/03/17/a-surgical-procedures-risks-unmentioned/
  4. Centers for Disease Control and Prevention. (2014, March 12). Uterine Cancer. Retrieved from: http://www.cdc.gov/cancer/uterine/
  5. Grady, D. (2014, February 6). Uterine Surgical Technique Is Linked to Abnormal Growths and Cancer Spread. Retrieved from: http://www.nytimes.com/2014/02/07/health/uterine-surgical-technique-is-linked-to-abnormal-growths-and-cancer-spread.html
  6. Mapes, D. (2014, July 30). 'They blasted it all over.' Retrieved from https://www.fredhutch.org/en/news/center-news/2014/07/Controversial-morcellation-procedure-fibroids-spread-cancer.html
  7. Sanfilippo, J.S. (2014, July 30). Hysteroscopic morcellation – a very different entity. Retrieved from https://www.mdedge.com/obgyn/article/86097/hysteroscopic-morcellation-very-different-entity
  8. Sarcoma Foundation of America. (n.d.). Sarcoma Subtypes: Uterine Leiomyosarcoma. Retrieved from: http://www.curesarcoma.org/
  9. Tissue Extraction Task Force. (2014, May 6). Morcellation During Uterine Tissue Extraction. American Association of Gynecologic Laparoscopists. Retrieved from: http://www.aagl.org/wp-content/uploads/2014/05/Tissue_Extraction_TFR.pdf
  10. U.S. Food and Drug Administration. (2014, November 25). Immediately in effect guidance document: Product labeling for laparoscopic power morcellators. Retrieved from http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM424123.pdf
  11. U.S. Food and Drug Administration. (2014, April 17.) Laparoscopic Uterine Power Morcellation in Hysterectomy and Myomectomy: FDA Safety Communication. Retrieved from: https://www.fda.gov/medicaldevices/productsandmedicalprocedures/surgeryandlifesupport/ucm584463.htm
  12. U.S Food and Drug Administration. (2014, November 24.) Laparoscopic Uterine Power Morcellation in Hysterectomy and Myomectomy: FDA Safety Communication. Retrieved from http://wayback.archive-it.org/7993/20170722215727/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm424443.htm
  13. Wright, J.D., Tergas, A. I., Burke, W.M. (2014, September 24). Uterine Pathology in Women Undergoing Minimally Invasive Hysterectomy Using Morcellation. Retrieved from: http://jamanetwork.com/journals/jama/fullarticle/1890400
  14. Weaver, M. and Abraham, J. (2007, April). An Introduction to Leiomyosarcoma of the Bone and Soft Tissue. The Liddy Shriver Sarcoma Initiative. Retrieved from: http://sarcomahelp.org/leiomyosarcoma.html
View All Sources
Who Am I Calling?

Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.

Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.

(888) 645-1617